ArticleBMC cancer2026
Checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors prior to chest radiotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have become a standard treatment method for lung cancer in recent years. While they improve survival, they are associated with adverse effects affecting the safety of patients and their subsequent treatment. This study aimed to assess checkpoint inhibitor pneumonitis (CIP) in lung cancer patients receiving ICIs prior to chest radiotherapy (chest-RT). MATERIALS AND
methodsBetween October 2018 and September 2024, 52 lung cancer patients who received ICIs before chest-RT were enrolled in the hospital. Clinical characteristics, treatment details, incidence of CIP, prognosis, and hypersensitive C-reactive protein (hsCRP) levels were collected. Associations between clinical characteristics, treatment, hsCRP, and CIP were analyzed.
resultsAmong patients treated with ICIs before chest-RT, 21.2% (11/52) developed CIP. Compared with patients without CIP, those with CIP had higher proportions of T4 stage (54.5% vs. 31.7%), N3 stage (45.5% vs. 26.8%), and stage IIIc-IV disease (45.5% vs. 22.0%) although these differences are not statistically significant. The impact of treatment on CIP was significant for the percent volume of lung receiving ≥ 20 Gy (V20, < 28% vs. ≥ 28%), P = 0.042. Among 11 patients with CIP, two patients died from CIP and three were unable to complete radiotherapy due to toxicity. The mean value of the highest hsCRP in patients with CIP were 79.3 mg/L (25.6-195.5 mg/L), and pretreatment mean values of hsCRP for these patients were 5.7 mg/L (0.5-11.9 mg/L), compared to the hightest hsCRP 23.8 mg/L (0.9-190.3 mg/L) in patients without CIP.
conclusionsLung cancer patients receiving ICIs prior to chest-RT have a relatively high incidence of CIP, particularly those with high V20. Monitoring hsCRP, a simple and cost-effective biomarker, may allow clinicians to detect CIP early and intervene promptly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.